Brian Cheng Analyst Performance

Biotech Analyst at JPMorgan Chase & Co.

Brian Cheng is a stock analyst at JPMorgan Chase & Co. in the medical sector, covering 16 publicly traded companies. Over the past year, Brian Cheng has issued 21 stock ratings, including buy, hold, and sell recommendations. While full access to Brian Cheng's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Brian Cheng's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

23 Last 3 Years

Buy Recommendations

65.22% 15 Buy Ratings

Companies Covered

16 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	65.2%	15 ratings
Hold	21.7%	5 ratings
Sell	13.0%	3 ratings

Out of 23 total stock ratings issued by Brian Cheng at JPMorgan Chase & Co., the majority (65.2%) have been Buy recommendations, followed by 21.7% Hold and 13.0% Sell.

Best & Worst Calls

• Best Call

  000.0%

  PSTX

  Feb 2022

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  00.0%

  PSTX

  Jan 2022

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	16 companies

Brian Cheng, an analyst at JPMorgan Chase & Co., currently covers 16 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 16 companies	100.0%

Brian Cheng of JPMorgan Chase & Co. specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 15 companies	93.8%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	6.3%

Brian Cheng's Ratings History at JPMorgan Chase & Co.

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
ALLO Allogene Therapeutics	10/10/2025	Reiterated Rating	$1.51		Underweight	$0.00 00.00% ROI
PLRX Pliant Therapeutics	10/10/2025	Reiterated Rating	$1.54		Underweight	$0.00 00.00% ROI
ABSI Absci	10/2/2025	Initiated Coverage	$3.13		Overweight	$0.00 00.00% ROI
IMVT Immunovant	9/30/2025	Lower Price Target	$16.06	$33.00	Overweight	$0.00 00.00% ROI
CGON CG Oncology	9/26/2025	Boost Price Target	$36.48	$47.00	Overweight	$0.00 00.00% ROI
CRSP CRISPR Therapeutics	9/18/2025	Initiated Coverage	$59.07	$70.00	Overweight	$0.00 00.00% ROI
ROIV Roivant Sciences	9/18/2025	Boost Price Target	$15.42	$20.00	Overweight	$0.00 00.00% ROI
PGEN Precigen	8/15/2025	Upgrade	$1.85		Neutral	$0.00 00.00% ROI
IMVT Immunovant	8/12/2025	Lower Price Target	$15.26	$37.00	Overweight	$0.00 00.00% ROI
IMNM Immunome	8/7/2025	Lower Price Target	$9.87	$22.00	Overweight	$0.00 00.00% ROI
ALLO Allogene Therapeutics	8/4/2025	Reiterated Rating	$1.08		Neutral	$0.00 00.00% ROI
BPMC Blueprint Medicines	6/2/2025	Reiterated Rating	$127.71	$129.00	Neutral	$0.00 00.00% ROI
ITOS iTeos Therapeutics	5/13/2025	Downgrade	$8.02	$8.00	Neutral	$0.00 00.00% ROI
CGON CG Oncology	5/2/2025	Initiated Coverage	$27.74	$41.00	Overweight	$0.00 00.00% ROI
AAPG Ascentage Pharma Group International	3/27/2025	Initiated Coverage	$18.37		Overweight	$0.00 00.00% ROI
ITOS iTeos Therapeutics	3/6/2025	Lower Price Target	$7.11	$15.00	Overweight	$0.00 00.00% ROI
PTGX Protagonist Therapeutics	3/4/2025	Boost Price Target	$38.50	$57.00	Overweight	$0.00 00.00% ROI
NTLA Intellia Therapeutics	2/28/2025	Reiterated Rating	$10.86	$13.00	Neutral	$0.00 00.00% ROI
PTGX Protagonist Therapeutics	2/4/2025	Boost Price Target	$37.66	$53.00	Overweight	$0.00 00.00% ROI
BPMC Blueprint Medicines	2/4/2025	Boost Price Target	$112.35	$129.00	Overweight	$0.00 00.00% ROI
CRGX CARGO Therapeutics	1/30/2025	Downgrade	$13.19		Underweight	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.